DK3190113T3 - Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist - Google Patents
Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist Download PDFInfo
- Publication number
- DK3190113T3 DK3190113T3 DK15831451.8T DK15831451T DK3190113T3 DK 3190113 T3 DK3190113 T3 DK 3190113T3 DK 15831451 T DK15831451 T DK 15831451T DK 3190113 T3 DK3190113 T3 DK 3190113T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds used
- tlr7 agonist
- pyrrolopyrimidine compounds
- pyrrolopyrimidine
- tlr7
- Prior art date
Links
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410405136.0A CN105367576A (zh) | 2014-08-15 | 2014-08-15 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN201510392499 | 2015-07-06 | ||
| PCT/CN2015/086909 WO2016023511A1 (zh) | 2014-08-15 | 2015-08-14 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3190113T3 true DK3190113T3 (da) | 2021-06-07 |
Family
ID=55303885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15831451.8T DK3190113T3 (da) | 2014-08-15 | 2015-08-14 | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962388B2 (da) |
| EP (1) | EP3190113B1 (da) |
| JP (2) | JP6328341B2 (da) |
| KR (2) | KR102215609B1 (da) |
| CN (4) | CN110759916B (da) |
| AU (3) | AU2015303558B2 (da) |
| BR (1) | BR112017002811B1 (da) |
| CA (1) | CA2958097C (da) |
| CL (1) | CL2017000379A1 (da) |
| DK (1) | DK3190113T3 (da) |
| EA (1) | EA032824B1 (da) |
| ES (1) | ES2875313T3 (da) |
| HR (1) | HRP20210927T1 (da) |
| HU (1) | HUE054672T2 (da) |
| IL (2) | IL250586B (da) |
| LT (1) | LT3190113T (da) |
| MX (1) | MX386981B (da) |
| MY (1) | MY190026A (da) |
| PH (2) | PH12017500281B1 (da) |
| PL (1) | PL3190113T3 (da) |
| PT (1) | PT3190113T (da) |
| SG (2) | SG11201701169XA (da) |
| SI (1) | SI3190113T1 (da) |
| UA (1) | UA117634C2 (da) |
| WO (1) | WO2016023511A1 (da) |
| ZA (1) | ZA201803736B (da) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| MX386981B (es) * | 2014-08-15 | 2025-03-19 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). |
| CN107580596B (zh) | 2015-05-08 | 2020-07-14 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物 |
| SG11201802769RA (en) | 2015-10-29 | 2018-05-30 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| CN108349982B (zh) | 2015-11-05 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物 |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| HRP20220479T1 (hr) | 2016-06-01 | 2022-05-27 | Athira Pharma, Inc. | Spojevi |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| PE20190476A1 (es) | 2016-08-29 | 2019-04-04 | Hoffmann La Roche | Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica |
| EP3510033B1 (en) | 2016-09-09 | 2021-11-24 | Novartis AG | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| CN109715214B (zh) | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗 |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| WO2018078149A1 (en) * | 2016-10-31 | 2018-05-03 | F. Hoffmann-La Roche Ag | Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| JP6932394B2 (ja) | 2016-11-11 | 2021-09-08 | ヘポ ファーマスーティカル カンパニー リミテッド | 含窒素複素環化合物、製造方法、中間体、医薬組成物及び応用 |
| KR20190084991A (ko) * | 2016-11-28 | 2019-07-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도 |
| EP3636646A4 (en) * | 2017-05-18 | 2020-12-09 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
| AU2018386201A1 (en) | 2017-12-15 | 2020-07-30 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| JP7289301B2 (ja) | 2017-12-18 | 2023-06-09 | ブリストル－マイヤーズ スクイブ カンパニー | ４－アザインドール化合物 |
| CN111511730B (zh) | 2017-12-19 | 2023-07-25 | 百时美施贵宝公司 | 可用作tlr抑制剂的被酰胺取代的吲哚化合物 |
| SG11202005704RA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | 6-azaindole compounds |
| US11878975B2 (en) | 2017-12-19 | 2024-01-23 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| CA3085937A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN112105620B (zh) | 2018-05-25 | 2026-02-24 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN116098905A (zh) * | 2018-10-12 | 2023-05-12 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的tlr7激动剂及其药物组合 |
| US11998537B2 (en) | 2018-10-24 | 2024-06-04 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
| WO2020086503A1 (en) | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| JP7637328B2 (ja) | 2019-02-07 | 2025-02-28 | ベイジーン リミテッド | Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113747899B (zh) * | 2019-03-15 | 2023-11-21 | 正大天晴药业集团股份有限公司 | 用于治疗乙型肝炎的Toll样受体激动剂 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| JP2022530444A (ja) | 2019-04-23 | 2022-06-29 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｔｌｒ７アゴニストを含む固体医薬組成物 |
| KR102904576B1 (ko) | 2019-05-09 | 2025-12-24 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 벤즈이미다졸론 화합물 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| KR20220041838A (ko) * | 2019-08-02 | 2022-04-01 | 베이진 엘티디 | Tlr8 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| JP7749545B6 (ja) * | 2019-09-29 | 2025-11-14 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｔｌｒ７作用薬を含む薬物の組み合わせ |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021067326A1 (en) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| ES2965164T3 (es) | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| JP2023512207A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| KR20220132593A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| US20230144824A1 (en) | 2020-01-27 | 2023-05-11 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115151546A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512204A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| EP4115901A4 (en) | 2020-03-02 | 2024-04-10 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| EP4194010A4 (en) | 2020-08-04 | 2025-03-26 | Progeneer Inc. | Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof |
| WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| CN114805392A (zh) * | 2021-01-20 | 2022-07-29 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| WO2022206752A1 (zh) | 2021-03-29 | 2022-10-06 | 正大天晴药业集团股份有限公司 | Toll样受体7激动剂和抗PD-L1抗体的药物联合 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9020931D0 (en) * | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
| TW552261B (en) | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
| CA2311742C (en) | 1997-11-28 | 2009-06-16 | Sumitomo Pharmaceuticals Co., Ltd. | 6-amino-9-benzyl-8-hydroxypurine derivatives |
| CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
| JP2009504803A (ja) * | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒアゴニスト |
| ES2456964T3 (es) * | 2007-02-07 | 2014-04-24 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| SI2170888T1 (sl) * | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| EP2571882A1 (en) * | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
| DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| US9139590B2 (en) * | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| EA035327B1 (ru) * | 2012-10-10 | 2020-05-28 | Янссен Сайенсиз Айрлэнд Юси | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний |
| CA2890201A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| WO2014081643A1 (en) * | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| PL2922549T3 (pl) * | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nowe związki |
| WO2015124591A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
| KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
| SG11201608299TA (en) | 2014-05-01 | 2016-11-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| MX386981B (es) * | 2014-08-15 | 2025-03-19 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2015
- 2015-08-14 MX MX2017002028A patent/MX386981B/es unknown
- 2015-08-14 JP JP2017527961A patent/JP6328341B2/ja active Active
- 2015-08-14 ES ES15831451T patent/ES2875313T3/es active Active
- 2015-08-14 EP EP15831451.8A patent/EP3190113B1/en active Active
- 2015-08-14 KR KR1020177007194A patent/KR102215609B1/ko active Active
- 2015-08-14 DK DK15831451.8T patent/DK3190113T3/da active
- 2015-08-14 AU AU2015303558A patent/AU2015303558B2/en active Active
- 2015-08-14 PL PL15831451T patent/PL3190113T3/pl unknown
- 2015-08-14 PT PT158314518T patent/PT3190113T/pt unknown
- 2015-08-14 LT LTEP15831451.8T patent/LT3190113T/lt unknown
- 2015-08-14 CN CN201911022725.XA patent/CN110759916B/zh active Active
- 2015-08-14 SG SG11201701169XA patent/SG11201701169XA/en unknown
- 2015-08-14 CN CN202110224402.XA patent/CN112898308A/zh active Pending
- 2015-08-14 MY MYPI2017700489A patent/MY190026A/en unknown
- 2015-08-14 UA UAA201702350A patent/UA117634C2/uk unknown
- 2015-08-14 US US15/503,977 patent/US9962388B2/en active Active
- 2015-08-14 SG SG10201809918RA patent/SG10201809918RA/en unknown
- 2015-08-14 HR HRP20210927TT patent/HRP20210927T1/hr unknown
- 2015-08-14 BR BR112017002811-5A patent/BR112017002811B1/pt active IP Right Grant
- 2015-08-14 EA EA201790389A patent/EA032824B1/ru unknown
- 2015-08-14 KR KR1020197024042A patent/KR20190098277A/ko not_active Ceased
- 2015-08-14 CN CN201580041989.3A patent/CN106661034B/zh active Active
- 2015-08-14 CN CN201911020774.XA patent/CN110938076B/zh active Active
- 2015-08-14 HU HUE15831451A patent/HUE054672T2/hu unknown
- 2015-08-14 CA CA2958097A patent/CA2958097C/en active Active
- 2015-08-14 WO PCT/CN2015/086909 patent/WO2016023511A1/zh not_active Ceased
- 2015-08-14 SI SI201531613T patent/SI3190113T1/sl unknown
-
2017
- 2017-02-14 IL IL250586A patent/IL250586B/en active IP Right Grant
- 2017-02-14 CL CL2017000379A patent/CL2017000379A1/es unknown
- 2017-02-15 PH PH12017500281A patent/PH12017500281B1/en unknown
-
2018
- 2018-04-17 JP JP2018079330A patent/JP6639551B2/ja active Active
- 2018-04-17 US US15/955,523 patent/US10555949B2/en active Active
- 2018-06-06 ZA ZA2018/03736A patent/ZA201803736B/en unknown
- 2018-10-01 AU AU2018236899A patent/AU2018236899B2/en active Active
-
2019
- 2019-10-22 AU AU2019253788A patent/AU2019253788C1/en active Active
-
2020
- 2020-07-16 PH PH12020551089A patent/PH12020551089A1/en unknown
- 2020-08-25 IL IL276908A patent/IL276908A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276908A (en) | Use of pyrrolopyrimidine compounds as an agonist for TLR7 | |
| DK3436461T3 (da) | Pyrrolotriazinforbindelser som tam-inhibitorer | |
| IL250923A0 (en) | Novel compounds as rearranged during transfection (ret) inhibitors | |
| DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
| PT3769781T (pt) | Formulação anti-ifnar1 estável | |
| LT3197883T (lt) | Nauji junginiai | |
| DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3209656T3 (da) | Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| HUE042964T2 (hu) | Szubsztituált dihidro-izokinolinon vegyületek | |
| DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
| KR102494289B9 (ko) | 활성 혼합물 | |
| PT3116498T (pt) | Formulação para análogos anticolinérgicos suaves | |
| DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer | |
| DK3177624T3 (da) | Imidazopyridazinforbindelser | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| DK3792251T3 (da) | Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika | |
| HUE039805T2 (hu) | Új szulfonilaminobenzamid vegyületek | |
| DK3126354T3 (da) | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer | |
| DK3173071T4 (da) | Maropitantformulering | |
| LT3233862T (lt) | Imidazopiridazino dariniai, kaip pi3kbeta slopikliai | |
| DK3148513T3 (da) | Ceritinib-formulering | |
| DK3233839T3 (da) | Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer |